Bausch + Lomb, a leading supplier of contact lenses and eyecare products, raised $630 million by offering 35 million shares (100% secondary) at $18, below the $21 to $24 range.
The company is being carved out of publicly-traded parent Bausch Health Companies (BHC).
Bausch + Lomb plans to list on the NYSE and the TSX on Friday under the symbol BLCO. Morgan Stanley, Goldman Sachs, Citi, J.P. Morgan, Barclays, BofA Securities, Guggenheim Securities, Jefferies, Evercore ISI, Wells Fargo Securities, and Deutsche Bank acted as joint bookrunners on the deal.
